These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 38272714)

  • 21. Molecular Mechanisms and Therapeutics for the GAA·TTC Expansion Disease Friedreich Ataxia.
    Gottesfeld JM
    Neurotherapeutics; 2019 Oct; 16(4):1032-1049. PubMed ID: 31317428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Milestone in the Treatment of Ataxias: Approval of Omaveloxolone for Friedreich Ataxia.
    Subramony SH; Lynch DL
    Cerebellum; 2024 Apr; 23(2):775-777. PubMed ID: 37219716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ferroptosis as a Novel Therapeutic Target for Friedreich's Ataxia.
    Cotticelli MG; Xia S; Lin D; Lee T; Terrab L; Wipf P; Huryn DM; Wilson RB
    J Pharmacol Exp Ther; 2019 Apr; 369(1):47-54. PubMed ID: 30635474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the gene in Friedreich ataxia.
    Hebert MD
    Biochimie; 2008 Aug; 90(8):1131-9. PubMed ID: 18206656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Cardiac Calcium Handling Machinery is Remodeled in Friedreich's Ataxia.
    Czornobil R; Abou-Assali O; Remily-Wood E; Lynch DR; Noujaim SF; Chidipi B
    bioRxiv; 2023 Nov; ():. PubMed ID: 38014032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates.
    Reisman SA; Gahir SS; Lee CI; Proksch JW; Sakamoto M; Ward KW
    Drug Des Devel Ther; 2019; 13():1259-1270. PubMed ID: 31118567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Future Prospects of Gene Therapy for Friedreich's Ataxia.
    Ocana-Santero G; Díaz-Nido J; Herranz-Martín S
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dimethyl fumarate dosing in humans increases frataxin expression: A potential therapy for Friedreich's Ataxia.
    Jasoliya M; Sacca F; Sahdeo S; Chedin F; Pane C; Brescia Morra V; Filla A; Pook M; Cortopassi G
    PLoS One; 2019; 14(6):e0217776. PubMed ID: 31158268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liver Growth Factor (LGF) Upregulates Frataxin Protein Expression and Reduces Oxidative Stress in Friedreich's Ataxia Transgenic Mice.
    Calatrava-Ferreras L; Gonzalo-Gobernado R; Reimers D; Herranz AS; Casarejos MJ; Jiménez-Escrig A; Regadera J; Velasco-Martín J; Vallejo-Muñoz M; Díaz-Gil JJ; Bazán E
    Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27941692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study.
    Libri V; Yandim C; Athanasopoulos S; Loyse N; Natisvili T; Law PP; Chan PK; Mohammad T; Mauri M; Tam KT; Leiper J; Piper S; Ramesh A; Parkinson MH; Huson L; Giunti P; Festenstein R
    Lancet; 2014 Aug; 384(9942):504-13. PubMed ID: 24794816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging therapies in Friedreich's Ataxia.
    Zesiewicz TA; Hancock J; Ghanekar SD; Kuo SH; Dohse CA; Vega J
    Expert Rev Neurother; 2020 Dec; 20(12):1215-1228. PubMed ID: 32909841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dyclonine rescues frataxin deficiency in animal models and buccal cells of patients with Friedreich's ataxia.
    Sahdeo S; Scott BD; McMackin MZ; Jasoliya M; Brown B; Wulff H; Perlman SL; Pook MA; Cortopassi GA
    Hum Mol Genet; 2014 Dec; 23(25):6848-62. PubMed ID: 25113747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frataxin deficiency alters gene expression in Friedreich ataxia derived IPSC-neurons and cardiomyocytes.
    Angulo MB; Bertalovitz A; Argenziano MA; Yang J; Patel A; Zesiewicz T; McDonald TV
    Mol Genet Genomic Med; 2023 Jan; 11(1):e2093. PubMed ID: 36369844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Friedreich ataxia: Detection of GAA repeat expansions and frataxin point mutations.
    Pandolfo M
    Methods Mol Med; 2006; 126():197-216. PubMed ID: 16930014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exonic deletions of FXN and early-onset Friedreich ataxia.
    Anheim M; Mariani LL; Calvas P; Cheuret E; Zagnoli F; Odent S; Seguela C; Marelli C; Fritsch M; Delaunoy JP; Brice A; Dürr A; Koenig M
    Arch Neurol; 2012 Jul; 69(7):912-6. PubMed ID: 22409940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Friedreich's ataxia.
    Alper G; Narayanan V
    Pediatr Neurol; 2003 May; 28(5):335-41. PubMed ID: 12878293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia.
    Li L; Voullaire L; Sandi C; Pook MA; Ioannou PA; Delatycki MB; Sarsero JP
    PLoS One; 2013; 8(2):e55940. PubMed ID: 23418481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Friedreich's ataxia: the vicious circle hypothesis revisited.
    Bayot A; Santos R; Camadro JM; Rustin P
    BMC Med; 2011 Oct; 9():112. PubMed ID: 21985033
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Nrf2-Inducer Prevents Mitochondrial Defects and Oxidative Stress in Friedreich's Ataxia Models.
    Abeti R; Baccaro A; Esteras N; Giunti P
    Front Cell Neurosci; 2018; 12():188. PubMed ID: 30065630
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities.
    Santos R; Lefevre S; Sliwa D; Seguin A; Camadro JM; Lesuisse E
    Antioxid Redox Signal; 2010 Sep; 13(5):651-90. PubMed ID: 20156111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.